Sentences with phrase «novel diabetes therapies»
Not exact matches
«Using Streptozotocin - induced type I diabetes and cornea epithelial wounding experimental models, we made novel observations that may soon lead to innovative therapies to treat DPN and ulcerations of the cornea and skin in diabetic patients,» said Yu.
https://www.sciencedaily.com/
«While expanding beta cell mass may still be desirable for future diabetes therapy, improving the local environment of the otherwise healthy aged beta cell could prevent age - associated deterioration in glucose homeostasis and thereby promote healthy ageing, which is conceptually novel and highly exciting,» says Per - Olof Berggren.
The discovery provides an opportunity to pursue the development of novel drug therapies to address obesity, type 2 diabetes and related metabolic diseases.
It demonstrates a completely novel mechanism of predisposition to diabetes that could lead to novel therapies,» says Adrian Vella, M.D., Mayo Clinic endocrinologist and senior author of the study.
«The addition of osteocalcin as a metabolic regulator may one day lead to novel therapies, but we need to understand much better how it works and how it fits into physiology before such therapies can be attempted in humans,» says endocrinologist Mitch Lazar, director of the Institute for Diabetes, Obesity, and Metabolism at the University of Pennsylvania.
The technique «potentially provides ways to create model systems for studying the genetic basis of diabetes, or to discover novel therapies to enhance existing β cells,» Ferrer says.
«'' Yet again, a world - class team of scientists has suggested another novel cell - based therapy for diabetes.
ViaCyte, a private company that has emerged as a leader in the field of regenerative medicine, is currently focused on developing a novel cell therapy for the treatment of diabetes.
World Advanced Therapies and Regenerative Medicine Congress Speaker: Mark Zimmerman, Ph.D., Vice President, Operations and Business Development Presentation: New data on a novel stem cell combination product for diabetes — development and clinical update Date / Time: May 17, 3:30 PM BST Location: Business Design Centre, London
«These events offer several venues and platforms to share the exciting progress ViaCyte is making in developing novel cell replacement therapies for diabetes,» said Paul Laikind, PhD, President and CEO of ViaCyte.
ViaCyte is a privately - held, clinical - stage regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.
«These findings provide hope that long - term improvements in glucose control may alter the course of kidney disease in people with type 1 diabetes,» said JDRF program director Helen Nickerson, Ph.D. «This reinforces the importance of improved glycemic control as we pursue novel therapies to slow or reverse loss of kidney function.»
San Diego, August 1, 2017 — ViaCyte, Inc., a privately - held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.
ViaCyte is a privately held, clinical - stage regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.